Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Primary tabs
View
(active tab)
Miltenyi Biotec
April 25, 2016
The next CAR-T target generates promise and caution
October 22, 2015
SITC preview – Macrogenics’ time to shine
May 21, 2015
Bluebird’s investors relieved by sickle cell abstract data
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
December 13, 2018
Vantage 2019 Preview
Editor's Picks
June 18, 2019
Array-size deals don’t come around too often
June 06, 2019
Takeda casts doubt on the remaining approach to amyloidosis
June 14, 2019
EHA 2019 – Global Blood faces sickle cell questions
June 12, 2019
Liquid biopsies: the future of cancer diagnosis?
May 24, 2019
Time to restock big pharma’s leaking pipeline
